Please switch to a supported browser to continue using this website. Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.
CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL -including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor - provides lifesaving products to patients in more than 100 countries and employs 32,000 people.
Biotherapies & Rare disease
VACCINES
IRON DEFICIENCY & NEPHROLOGY
CSL At A Glance
40+
Countries of operations around the world
32,000+
employees around the world
US$13.3
billion in revenue FY23
2,000+
R&D employees
US$5.1
billion in R&D investments in the last 5 years to advance product pipeline
342
Plasma collection centres across China, Europe and North America
Figures current as at publishing of 2023 Annual Report
Our Values
CSL's strong commitment to living our values has guided us for many decades. Our values are fundamental to our
success - helping us to save lives, protect the health of people and earn our reputation as a trusted and reliable global
leader. They are at the core of how our employees interact with each other, make decisions and solve problems.
CSL is driving sustainable growth to bring lifesaving therapies to patients and protect public health across the globe.
We are focused on delivering across our therapeutic areas through innovation and our tireless approach to efficiency and reliable supply.
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.